, Tracking Stock Market Picks
Enter Symbol:

up 59.32 %

ARDEA BIOSCIENCES (RDEA) rated Outperform with price target $29 by Mehta Partners

Posted on: Wednesday,  Jul 14, 2010  11:25 AM ET by Mehta Partners

Mehta Partners rated Outperform ARDEA BIOSCIENCES (NASDAQ: RDEA) on 07/14/2010, when the stock price was $20.06. Since
then, ARDEA BIOSCIENCES has gained 59.32% as of 06/19/2012's recent price of $31.96.
If you would have followed this Mehta Partners's recommendation on RDEA, you would have gained 59.32% of your investment in 706 days.

Ardea Biosciences, Inc. is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of human immunodeficiency virus (HIV), cancer and inflammatory diseases, including gout. The Company's portfolio of product candidates include RDEA806 and 2nd generation non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV indication; RDEA594 for gout; RDEA119 for cancer; RDEA119 for inflammation, and mitogen-activated ERK kinase (MEK) inhibitor for cancer/inflammation.

The reputation of Mehta Partners rests on a body of work that began in 1980s with the aim of "maintaining a birds-eye view of the pharma, biotech and healthcare industry worldwide." Viren Mehta, founder and managing partner of Mehta Partners, formulated this objective and emphasized that the Biotechnology and Pharmaceutical segments are ultimately indistinguishable parts of the BioPharma industry; and that BioPharma is a truly global industry that is best understood when viewed from a worldwide perspective.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
7/14/2010 11:25 AM Buy
20.06 29.00
as of 12/31/2010
1 Week down  -0.80 %
1 Month up  16.01 %
3 Months up  12.13 %
1 YTD up  28.56 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy